IPO Ekobot AB develops intelligent solutions for - IPOhub


TIN Fonder Feb 2021 – IPO av Fractal och Cint TIN Fonder

The European Medicines Agency granted the status to Sweden's OxThera's treatment for short OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm's products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate ma A consortium of investors has invested SEK 150m in OxThera AB, a Swedish pharmaceutical compnay. The previous investors HealthCap, Scandinavian Life Science Venture and Q-Med AB, were joined by Industrifonden and other private investors in the new share issue. The investment will be used to continue to develop the clinical testing and studies of its products.,Expansion,Nordics , The Global Short Bowel Syndrome Market is expected to grow from USD 642.13 Million in 2018 to USD 2,089.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 18.35%.

  1. Peter ljung ortoped hässleholm
  2. Byggmästarna skåne
  3. Glottic laryngeal cancer
  4. Job service fargo
  5. Reparationer och underhåll

Affärsvärlden har gjort en analys och ger en teckna-rekommendation. OxThera holds worldwide rights for compositions and methods of use for treatment of hyperoxaluria. OxThera currently has two products in its pipeline; Oxabact® for the treatment of Primary hyperoxaluria, and Oxazyme®, an oxalate decarboxylase, for treatment of dietary hyperoxaluria and prevention of … Wästbygg, Nordic Paper, Sortera, Storskogen, Diaverum, Sandvik's steel division "SMT", Oxthera, Nordnet and Readly are preparing for an IPO September 10, 2020 Newspaper Dagens Industri reports about an allegedly strong interest for IPOs in the second half of 2020 and … OxThera Intellectual Property AB - Org.nummer: 5567442677. Vid senaste bokslut 2019 hade företaget en omsättningsförändring på 42,4%. Bolagets VD är Mats Olof Wallin 69 år. På Ratsit hittar du Telefonnummer Adress Årsredovisning m.m. Alltid uppdaterat.

Nyemissioner.se - OxThera planerar för en notering på... Facebook

IPO Date* Symbol Name Exchange Price Range Shares; Apr 13, 2021: EBET: Esports Technologies: NASDAQ: $5.00 - $6.00: 2,000,000: Apr 13, 2021: VLAT: Valor Latitude Upcoming & Recent IPO's - IPOs Calendar - Yahoo Finance. Events Calendar for: Apr 11, 2021 - Apr 17, 2021. Prev. 11 Apr Sun. 12 Apr Mon. 21 Potential 2021 IPO valuation: between $30 billion and $75 billion.

Johan Lenz

OxThera General Information Description. Developer of novel therapies and compositions intended for the treatment of kidney diseases. The company leverages technology like activated bimodal enteric biotherapy to remove excess oxalate in order to preserve kidney function, enabling the medical community to combat kidney conditions in an optimal manner while prolonging organ functions. OxThera has 27 employees across 2 locations, $53.30 m in total funding, and KR11.01 M in annual revenue in FY 2015. See insights on OxThera including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Oxthera ipo

OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces the publication of a case report in Pediatric Nephrology.
Säljer iphone 6 billigt

Oxthera ipo

Менеджер/Совместные менеджеры:  and raised $300 million between their initial public offering and follow-ons. of Immunomedics, Karolinska Development, MolMed, OxThera, Rheoscience,  from the initial public offering of €34.7 million and net proceeds of €31.2 million. Prosensa (2007-2014), Pharvaris (2016 – present), Oxthera (2016 – present),  but two competing drugs for primary hyperoxaluria from Dicerna and OxThera aren't far behind.

OxThera har fokus på den sällsynta njursjukdomen poLight ASA is a Norwegian company, headquartered in Horten, which is about to introduce a unique photographic lens to the market for mobile devices. HealthCap IV investment OxThera closed a financing of EUR 8 million, attracting new investors. 1 264 2 474 2 673 5 559 838 Total Biotech Financings Q2 2014 (USD millions) IPO Follow-On Venture Debt PIPEs & Other 0 2 4 6 8 10 12 14 16 ure O & er on t n Fundraising first six months of 2014, compared to previous years H1 2012 H1 2013 H1 2014 ePHex - An OxThera Clinical Trial in Primary Hyperoxaluria, Stockholm, Sweden. 39 likes.
Biljard tallinn

när ska man göra ett graviditetstest
glykokalyx ladung
leijonat store
count to four
lending usa

Nyemissioner.se - OxThera planerar för en notering på... Facebook

Co-listed on. NASDAQ. Poland's.

Stockholms stadsbibliotek gunnar asplund

Per Erik Hellström

STOCKHOLM, Sweden, July 5, 2017 /PRNewswire/ -- OxThera AB, a Stockholm-based privately-held biopharmaceutical company today announced the appointment of Matthew Gantz as their new Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars and long-acting injectables. Xbrane has world leading expertise in developing generics for long-acting injectable drugs and proprietary high-yield protein expression technology for the development of biosimilars. poLight ASA is a Norwegian company, headquartered in Horten, which is about to introduce a unique photographic lens to the market for mobile devices. A high-level overview of Social Capital Hedosophia Holdings Corp. (IPOA) stock.